MedImmune Ventures Harvard Case Solution & Analysis

Ron Laufer is a newly designated Managing Director of Medlmmune Ventures, and the corporate arm of the AstraZeneca, a prominent pharmaceutical firm. It must be decided by Laufer whether to pursue a high potential, but really risky, early-stage investment. The decision Laufer will make will reflect his vision for MedImmune Ventures and more broadly the motivators he faces as a corporate venture capitalist.

PUBLICATION DATE: August 19, 2013 PRODUCT #: 814023-PDF-ENG

This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP

MedImmune Ventures Case Solution Other Similar Case Solutions like

MedImmune Ventures

Share This